Chemotherapy for malignant pleural mesothelioma

Current Treatment Options in Oncology

Volumn 12, Issue 2, 2011, Pages 181-188

  Garland, Linda L ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FOLIC ACID ANTAGONIST; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM; RALTITREXED; THYMIDYLATE SYNTHASE; VINBLASTINE; VITAMIN;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PLEURA MESOTHELIOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDIVIDUALIZED MEDICINE; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 79958044918     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0152-6     Document Type: Article

References (32)

1. N Merritt CJ Blewett JD Miller WF Bennett JE Young JD Urschel 2001 Survival after conservative (palliative) management of pleural malignant mesothelioma J Surg. Oncol. 78 171 174 11745800 10.1002/jso.1143 1:STN:280:DC%2BD3MnpsFOlsw%3D%3D (Pubitemid 33021078)
2. P Ruffie R Feld S Minkin Y Cormier A Boutan-Laroze R Ginsberg, et al. 1989 Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients J Clin Oncol. 7 1157 1168 2666592 1:STN:280:DyaL1MzivVCqtg%3D%3D (Pubitemid 19196542)
3. J Jassem R Ramlau A Santoro W Schuette A Chemaissani S Hong, et al. 2008 Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma J Clin Oncol. 26 1698 1704 18375898 10.1200/JCO.2006.09.9887 1:CAS:528:DC%2BD1cXltlWhs74%3D
4. MF Muers RJ Stephens P Fisher L Darlison CM Higgs E Lowry, et al. 2008 Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial Lancet 371 1685 1694 18486741 10.1016/S0140-6736(08)60727-8 1:CAS:528: DC%2BD1cXlvFymt7g%3D (Pubitemid 351671885)
5. NJ Vogelzang JJ Rusthoven J Symanowski C Denham E Kaukel P Ruffie, et al. 2003 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol. 21 2636 2644 12860938 10.1200/JCO.2003.11.136 1:CAS:528:DC%2BD2cXptlCktL4%3D (Pubitemid 46606305)
6. GL Ceresoli PA Zucali AG Favaretto F Grossi P Bidoli G Del Conte, et al. 2006 Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma J Clin Oncol. 24 1443 1448 16549838 10.1200/JCO.2005.04.3190 1:CAS:528:DC%2BD28Xjs1Ogt7Y%3D (Pubitemid 46622011)
7. JP van Meerbeeck R Gaafar C Manegold RJ van Klaveren EA Van Marck M Vincent, et al. 2005 Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol. 23 6881 6889 16192580 10.1200/JCO.20005.14.589
8. PJ Hollen RJ Gralla AM Liepa JT Symanowski JJ Rusthoven 2004 Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation Cancer 101 587 595 15274072 10.1002/cncr.20315 (Pubitemid 38970610)
9. A Bottomley R Gaafar C Manegold S Burgers C Coens C Legrand, et al. 2006 Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada Intergroup Study. J Clin Oncol. 24 1435 1442 1:CAS:528:DC%2BD28Xjs1Ogt7k%3D (Pubitemid 46622010)
10. DP van den Bogaert EM Pouw G van Wijhe RM Vernhout VF Surmont HC Hoogsteden, et al. 2006 Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma J Thorac. Oncol. 1 25 30 17409823 10.1097/01243894-200601000-00007 (Pubitemid 47164017)
11. SR Kalmadi C Rankin MJ Kraut AD Jacobs DP Petrylak DJ Adelstein, et al. 2008 Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810) Lung Cancer 60 259 263 18006112 10.1016/j.lungcan.2007.09.018 (Pubitemid 351609140)
12. HL Kindler JP van Meerbeeck 2002 The role of gemcitabine in the treatment of malignant mesothelioma Semin. Oncol. 29 70 76 11836671 10.1053/sonc.2002. 30232 1:CAS:528:DC%2BD38Xit1KltLg%3D
13. W Schutte T Blankenburg K Lauerwald J Schreiber I Bork B Wollscgkaeger, et al. 2003 A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma Clin Lung Cancer 4 294 297 14609447 10.3816/CLC.2003.n.009 (Pubitemid 36546414)
14. GV Scagliotti DM Shin HL Kindler MJ Vasconcelles U Keppler C Manegold, et al. 2003 Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma J Clin Oncol. 21 1556 1561 12697881 10.1200/JCO.2003.06.122 1:CAS:528:DC%2BD2cXptlCksLo%3D (Pubitemid 46594110)
15. JP Steele J Shamash MT Evans NH Gower MD Tischkowitz RM Rudd 2000 Phase II study of vinorelbine in patients with malignant pleural mesothelioma J Clin Oncol. 18 3912 3917 11099320 1:CAS:528:DC%2BD3cXptVSiu74%3D
16. HJ Lerner DA Schoenfeld A Martin G Falkson E Borden 1983 Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience Cancer 52 1981 1985 6627213 10.1002/1097-0142(19831201)52:11<1981::AID- CNCR2820521102>3.0.CO;2-P 1:STN:280:DyaL2c%2Fis1WjtQ%3D%3D (Pubitemid 14232234)
17. MD Magri A Veronesi S Foladore D De Giovanni C Serra F Crismancich, et al. 1991 Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE) - Mesothelioma Committee Tumori 77 49 51 2017799 1:STN:280:DyaK3M3gsFKhug%3D%3D
18. JP Steele CA O'Doherty J Shamash MT Evans NH Gower MD Tischkowitz, et al. 2001 Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma Ann. Oncol. 12 497 499 11398882 10.1023/A:1011139918558 1:STN:280: DC%2BD3MzjtFantg%3D%3D (Pubitemid 32472104)
19. Ceresoli, G. L., Zucali, P. A., De Vincenzo, F., Gianoncelli, L., Simonelli, M., Lorenzi, E., Ripa, C., Giordano, L., and Santoro, A. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer, 2011. This study reports the effectiveness of re-exposure to pemetrexed in MPM patients treated with front-line pemetrexed-based therapy with an excellent safety profile.
20. PA Janne AJ Wozniak CP Belani ML Keohan HJ Ross JA Polikoff, et al. 2006 Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program J Thorac. Oncol. 1 506 512 17409909 10.1097/01243894-200607000-00002 (Pubitemid 47181396)
21. P Taylor B Castagneto G Dark M Marangolo GV Scagliotti RJ van Klaveren, et al. 2008 Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program J Thorac. Oncol. 3 764 771 18594323 10.1097/JTO.0b013e31817c73ec
22. J Stebbing T Powles K McPherson J Shamash P Wells MT Sheaff 2009 The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma Lung Cancer 63 94 97 18486273 10.1016/j.lungcan.2008.04.001 This study shows the efficacy and safety profile of single agent vinorelbine in the second line setting.
23. PA Zucali GL Ceresoli I Garassino F De Vincenzo R Cavina E Campagnoli, et al. 2008 Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma Cancer 112 1555 1561 18286536 10.1002/cncr.23337 1:CAS:528:DC%2BD1cXktlKrurs%3D (Pubitemid 351441168)
24. C Porta M Zimatore L Bonomi I Imarisio C Paglino A Sartore-Bianchi, et al. 2005 Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients Lung Cancer 48 429 434 15893013 10.1016/j.lungcan.2004.11.015 (Pubitemid 40693630)
25. K Fizazi H Doubre T Le Chevalier A Riviere J Viala C Daniel, et al. 2003 Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study J Clin Oncol. 21 349 354 12525529 10.1200/JCO.2003.05.123 1:CAS:528:DC%2BD2cXpsVWqs7Y%3D (Pubitemid 46606165)
26. DA Fennell JP Steele J Shamash MT Evans P Wells MT Sheaff, et al. 2007 Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma Cancer 109 93 99 17146783 10.1002/cncr.22366 1:CAS:528:DC%2BD2sXhtVKrtbs%3D (Pubitemid 46120198)
27. D Curran T Sahmoud P Therasse J Van Meerbeeck PE Postmus G Giaccone 1998 Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol. 16 145 152 9440736 1:STN:280:DyaK1c7gtFKrtA%3D%3D (Pubitemid 28041592)
28. Zucali P, Destro A Ceresoli G et al. The role of thymidylate syntase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. Presented at European Conference on Clinical Oncology (ECCO), 2009.Abstr ER-1513a. 2010.
29. L Righi MG Papotti P Ceppi A Bille E Bacillo L Molinaro, et al. 2010 Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy J Clin Oncol. 28 1534 1539 20177021 10.1200/JCO.2009.25.9275 1:CAS:528:DC%2BC3cXltFGhtr8%3D This study reports on the prognostic value of thymidylate synthase in the context of a clinical trial using pemetrexed-based therapy.
30. M Stark C Wichman I Avivi YG Assaraf 2009 Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia Blood 113 4362 4369 19131550 10.1182/blood-2008-08-173799 1:CAS:528:DC%2BD1MXlvVGitr8%3D
31. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med.Oncol. 2010.
32. C Reynolds C Obasaju MJ Schell X Li Z Zheng D Boulware, et al. 2009 Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer J Clin Oncol. 27 5808 5815 19884554 10.1200/JCO.2009.21.9766 1:CAS:528: DC%2BC3cXhtVWitrw%3D